When it looks like Behçet's syndrome but is something else: Differential diagnosis of Behcet's syndrome: a two-centre retrospective analysis.

Lötscher, Fabian; Kerstens, Floor; Krusche, Martin; Ruffer, Nikolas; Kötter, Ina; Turkstra, Franktien (2023). When it looks like Behçet's syndrome but is something else: Differential diagnosis of Behcet's syndrome: a two-centre retrospective analysis. Rheumatology, 62(11), pp. 3654-3661. Oxford University Press 10.1093/rheumatology/kead101

[img]
Preview
Text
kead101.pdf - Accepted Version
Available under License Publisher holds Copyright.

Download (573kB) | Preview

OBJECTIVE

To investigate the differential diagnostic spectrum in patients with suspected Behçet's syndrome (BS) in low prevalence regions. In addition, the number of patients fulfilling the ICBD criteria despite not having BS was evaluated.

METHODS

This retrospective analysis was performed in two referral centers for BS. Patients with confirmed BS (clinical diagnosis with fulfilment of ISG criteria or a score of ≥ 5 points in the ICBD criteria) were excluded. The remaining patients were divided into eleven differential diagnosis categories. If no definitive alternative diagnosis could be established, patients were termed 'probable BS' in case of (1) relapsing orogenital aphthosis in the absence of other causes and either HLA-B51 positivity, origin from an endemic area or presence of an additional typical BS symptom that is not part of the classification criteria or (2) with 3-4 points scored in the ICBD criteria.

RESULTS

In total 202 patients were included and categorized as follows: 58 patients (28.7%) as 'probable BS', 57 (28.2%) skin disease, 26 (12.9%) chronic pain syndrome, 14 (6.9%) eye disease, 11 (5.4%) spondyloarthropathy, 9 (4.5%) gastrointestinal disease, 7 (3.5%) neurological disease, 4 (2%) arthritis, 3 (1.5%) auto-inflammation, 3 (1.5%) connective tissue disease, 10 (5.0%) miscellaneous disease. HLA-B51 was positive in 55/132 (41.6%); 75/202 (37.1%) of the patients fulfilled the ICBD criteria.

CONCLUSION

In a low disease prevalence setting the straightforward application of the ICBD criteria may lead to overdiagnosis of BS. The differential diagnosis of BS is enormously broad. Clinicians should be aware that HLA-B51 positivity is still not considered as a diagnostic feature in BS.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Rheumatology and Immunology

UniBE Contributor:

Lötscher, Fabian

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1462-0324

Publisher:

Oxford University Press

Language:

English

Submitter:

Pubmed Import

Date Deposited:

06 Mar 2023 09:27

Last Modified:

04 Mar 2024 00:25

Publisher DOI:

10.1093/rheumatology/kead101

PubMed ID:

36864623

Uncontrolled Keywords:

Behçet’s syndrome HLA-B*51 classification criteria cohort differential diagnosis

BORIS DOI:

10.48350/179498

URI:

https://boris.unibe.ch/id/eprint/179498

Actions (login required)

Edit item Edit item
Provide Feedback